Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.

Autor: Fabbi, Marina1 (AUTHOR) fabbim@libero.it, Costa, Delfina2 (AUTHOR), Russo, Daniela3 (AUTHOR), Arenare, Laura4 (AUTHOR), Gaggero, Gabriele5 (AUTHOR), Signoriello, Simona6 (AUTHOR), Scambia, Giovanni7,8 (AUTHOR), Pisano, Carmela9 (AUTHOR), Colombo, Nicoletta10 (AUTHOR), Losito, Nunzia Simona11 (AUTHOR), Filaci, Gilberto1,12 (AUTHOR), Spina, Anna3 (AUTHOR), Califano, Daniela3 (AUTHOR), Scognamiglio, Giosuè11 (AUTHOR), Gadducci, Angiolo13 (AUTHOR), Mezzanzanica, Delia14 (AUTHOR), Bagnoli, Marina14 (AUTHOR), Ferrini, Silvano1 (AUTHOR), Canzonieri, Vincenzo15,16 (AUTHOR), Chiodini, Paolo6 (AUTHOR)
Zdroj: Diagnostics (2075-4418). Sep2022, Vol. 12 Issue 9, pN.PAG-N.PAG. 14p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje